 NEW YORK, March 10, 2021 PRNewswire -- Pomerantz LLP is investigating claims on behalf of investors of Xeris Pharmaceuticals, Inc. Xeris or the Company NASDAQ: XERS. Such investors are advised to contact Robert S. 